Form 8-K · Current Report · Filed 2024-11-18
Twist Bioscience Reports Fourth Quarter and Fiscal 2024 Financial Results
On November 18, 2024, Twist Bioscience Corporation announced its financial results for the fourth quarter and full fiscal year ended September 30, 2024.
- Filer
- Twist Bioscience Corporation TWST · NASDAQ
- Filed
- Accession
- 0001628280-24-048173
- CIK
- 0001581280
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
The announcement included a press release detailing the Company's financial performance for the period.
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$36.89
Next session
+12.0%
Since filing
+321.7%
Latest close
$155.56
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from TWST reporting the same item, with the next session's move:
Exhibits (1)
About Twist Bioscience Corporation
Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research. The company also supports advanced workflows such as targeted next-generation sequencing, CRISPR gene editing, mutagenesis, and DNA data storage. Its proprietary semiconductor-based DNA synthesis platform is designed to produce high-quality synthetic DNA at scale, helping customers move from design to experimentation more efficiently. Twist Bioscience Corporation serves biotechnology, pharmaceutical, industrial, and academic customers across multiple regions, making it an important supplier in the life sciences tools and synthetic biology market.
Never miss another TWST filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.